US grant · National Institutes of Health
The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) - Clinical Research Centers (U01 Clinical Trial Not Allowed)
Up to $500,000 Closes March 5, 2027
Official listing and how to apply
Source: Grants.gov · Last checked
Key facts
| Funder | National Institutes of Health |
|---|---|
| Part of | Department of Health and Human Services |
| Opportunity number | RFA-DK-28-213 |
| Amount per award | Up to $500,000 |
| Total funding available | $4,500,000 |
| Opens | November 3, 2026 |
| Closes | March 5, 2027 (115 days left) |
| Who can apply | Schools and universities, Businesses, Government, Nonprofits, Other (see listing), Tribal organizations |
| Applicant types listed | Special district governments; County governments; Public housing authorities/Indian housing authorities; Native American tribal organizations (other than Federally recognized tribal governments); State governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Native American tribal governments (Federally recognized); Independent school districts; Public and State controlled institutions of higher education; Small businesses; For profit organizations other than small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; City or township governments; Others (see text field entitled "Additional Information on Eligibility" for clarification) |
| State or area | Nationwide |
| Cost sharing or match | Not required |
| Status | Open |
| Source | Grants.gov |
| Last checked | November 10, 2026 |
About this grant
Summary from the official listing on Grants.gov:
This Notice of Funding Opportunity (NOFO) invites new applications to participate in the Diseases of Gastrointestinal Interoception Consortium (DGIC). The overall objectives of this consortium are to: 1) identify the underlying mechanisms that link altered GI interception more directly to GI dysmotility and symptoms; 2) identify disease or response biomarkers that better assess pathophysiology or treatment efficacy; and 3) leverage state-of-the-art technologies to identify novel therapeutic targets that could be assessed in future clinical trials.
This NOFO uses a cooperative agreement mechanism (U01) and runs in parallel with a companion NOFO ( RFA-DK-28-214) .
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Details are copied from the official source and can change. Check the official listing before you apply. Grant Writing Company is not affiliated with this funder.
Want an expert to write it with you?
Grant Writing Company researches funders, writes organization proposals to each funder's instructions, and checks the package before you submit. experience since 2006. Funders decide every award.